Southampton spinout Droplet Scientific raises £1.5M to bring lab tests to the bedside
What's the deal? Droplet ScientificDealroom has a profile for this one. Try Dealroom →, a University of SouthamptonDealroom has a profile for this one. Try Dealroom → spinout, has raised £1.5 million in the first close of its pre-seed round. DSW VenturesDealroom has a profile for this one. Try Dealroom → led the round, with TusPark Holdings and Hope Sky Capital participating.
What's the endgame? The company is building continuous biochemical monitoring technology for hospital bedsides. It aims to track critical chemical biomarkers in near real time — automated measurements as often as every 20 seconds.
Why now? Vital signs such as heart rate and blood oxygen can already be monitored continuously, but many chemical biomarkers still rely on intermittent blood sampling and lab analysis. In intensive care, that can mean readings only every few hours, leaving clinicians with limited visibility of fast-changing conditions.
The company's first product, AnalyteXDealroom has a profile for this one. Try Dealroom →, targets neuroscience intensive care units, where patients can deteriorate rapidly. Its platform combines microfluidic and optical technologies to miniaturise established biochemical assays, with potential uses across sepsis, trauma, and cardiogenic shock care.
Where the money goes: The funding will support early commercialisation, product development, regulatory certification, and expansion of the Southampton team. Droplet Scientific was founded by microfluidics expert Xize Niu and former Dyson engineer Junda Niu.
"Our vision is to bring the laboratory closer to the patient — providing accurate, automated and continuous biochemical information that can help clinicians recognise changes earlier," said founder Xize Niu.
The signal: The raise reflects growing investor appetite for technology that closes the gap between the lab and the bedside. If continuous biomarker monitoring proves clinically viable, it could reshape how hospitals manage rapidly evolving conditions — a shift from intermittent testing to real-time data streams.
Read more: businesssouth.org
Image credit: IBM Research
